HLX10 Clinical Trials
6 recruitingDrug
Phase 25Phase 31Phase 11
Showing 1–6 of 6 trials
Recruiting
Phase 2
Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
Resectable Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital46 enrolled1 locationNCT07457528
Recruiting
Phase 1
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors
Advanced/Metastatic Malignant Solid Tumors
Shanghai Henlius Biotech340 enrolled2 locationsNCT06115642
Recruiting
Phase 2
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
Carcinoma, Hepatocellular
Shanghai Henlius Biotech117 enrolled1 locationNCT06349980
Recruiting
Phase 2Phase 3
A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)
Metastatic Colorectal Cancer
Shanghai Henlius Biotech568 enrolled5 locationsNCT04547166
Recruiting
Phase 2
Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients
Limited Stage Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences55 enrolled2 locationsNCT05443646
Recruiting
Phase 2
A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy
MSI-H Solid Malignant Tumor
Shanghai Henlius Biotech108 enrolled33 locationsNCT03941574